主要文件

查看所有文档

SML0492

Zanamivir

Name: Zanamivir
Brand: SIGMA

≥98% (HPLC), Influenza viral neuraminidase inhibitor, powder

别名:

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₂H₂₀N₄O₇

化学文摘社编号:

139110-80-8

分子量:

332.31

UNSPSC Code:

12352200

PubChem Substance ID:

329825442

NACRES:

NA.77

MDL number:

MFCD00866966

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

Zanamivir, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +30 to +40°, c = 1 in H₂O

color

white to beige

solubility

H₂O: 10 mg/mL, clear

storage temp.

room temp

SMILES string

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChI key

ARAIBEBZBOPLMB-UFGQHTETSA-N

说明

Application

Zanamivir has been used:

as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
as an antiviral to study its effects on influenza B virus by plaque reduction assay

Biochem/physiol Actions

Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.

Zanamivir is an influenza viral neuraminidase inhibitor.

Still not finding the right product?

Explore all of our products under

pictograms

GHS07

signalword

Warning

hcodes

H302,H315,H319,H335

pcodes

P261 - P264 - P270 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Carl J Heneghan et al.

BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)

To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.

Javier Magano

Chemical reviews, 109(9), 4398-4438 (2009-06-23)

Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.

Benjamin O Fulton et al.

Journal of virology, 89(23), 12226-12231 (2015-09-25)

Influenza B virus is a human pathogen responsible for significant health and economic burden. Research into this pathogen has been limited by the lack of reporter viruses. Here we describe the development of both a replication-competent fluorescent influenza B reporter

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML0492-50MG	04061832633602
SML0492-10MG	04061837084706